retatrutide peptide triple hormone receptor agonist (Triple-Action Jab): Phase III trial results published in The Lancet reveal that this triple-hormone (targeting GLP-1, GIP, and glucagon receptors) achieves unprecedented retatrutide peptide obesity triple hormone
Pay in 4 interest-free payments of $6.22 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1




















![Tirzepatide vs. Semaglutide: Which GLP-1 Better Preserves Muscle? [SURMOUNT-5 Data]](https://www.clinicalnutritioncenter.com/wp-content/uploads/2026/04/research-image-2026-04-10.jpg)





